NEOGEN CORP (NEOG) Stock Fundamental Analysis
USA - NASDAQ:NEOG - US6404911066 - Common Stock
6.42 USD
+0.03 (+0.47%)
6.35 USD
-0.07 (-1.09%)
We assign a fundamental rating of 3 out of 10 to NEOG. NEOG was compared to 188 industry peers in the Health Care Equipment & Supplies industry. NEOG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NEOG has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year NEOG was profitable.
In the past year NEOG had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: NEOG reported negative net income in multiple years.
NEOG had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -30.88%, NEOG is in line with its industry, outperforming 43.09% of the companies in the same industry.
With a Return On Equity value of -49.23%, NEOG perfoms like the industry average, outperforming 51.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.88% | ||
| ROE | -49.23% | ||
| ROIC | N/A |
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of NEOG (46.39%) is comparable to the rest of the industry.
NEOG's Gross Margin has been stable in the last couple of years.
NEOG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
2. Health
2.1 Basic Checks
NEOG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NEOG has about the same amount of shares outstanding.
NEOG has more shares outstanding than it did 5 years ago.
NEOG has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.83, we must say that NEOG is in the distress zone and has some risk of bankruptcy.
NEOG has a Altman-Z score of 0.83. This is comparable to the rest of the industry: NEOG outperforms 52.66% of its industry peers.
A Debt/Equity ratio of 0.37 indicates that NEOG is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.37, NEOG is in line with its industry, outperforming 48.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.83 |
ROIC/WACCN/A
WACC7.71%
2.3 Liquidity
NEOG has a Current Ratio of 3.58. This indicates that NEOG is financially healthy and has no problem in meeting its short term obligations.
NEOG's Current ratio of 3.58 is fine compared to the rest of the industry. NEOG outperforms 65.43% of its industry peers.
NEOG has a Quick Ratio of 2.26. This indicates that NEOG is financially healthy and has no problem in meeting its short term obligations.
NEOG has a Quick ratio (2.26) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.58 | ||
| Quick Ratio | 2.26 |
3. Growth
3.1 Past
NEOG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.
NEOG shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -10.20% yearly.
NEOG shows a decrease in Revenue. In the last year, the revenue decreased by -2.77%.
The Revenue has been growing by 16.43% on average over the past years. This is quite good.
EPS 1Y (TTM)-25%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-42.86%
Revenue 1Y (TTM)-2.77%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-3.58%
3.2 Future
Based on estimates for the next years, NEOG will show a small growth in Earnings Per Share. The EPS will grow by 7.29% on average per year.
NEOG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.76% yearly.
EPS Next Y-25.82%
EPS Next 2Y2.51%
EPS Next 3Y6.43%
EPS Next 5Y7.29%
Revenue Next Year-7.61%
Revenue Next 2Y-3.02%
Revenue Next 3Y-1.03%
Revenue Next 5Y0.76%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 21.40, NEOG is valued on the expensive side.
Based on the Price/Earnings ratio, NEOG is valued cheaper than 80.32% of the companies in the same industry.
NEOG's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 25.56.
NEOG is valuated rather expensively with a Price/Forward Earnings ratio of 18.51.
Based on the Price/Forward Earnings ratio, NEOG is valued cheaply inside the industry as 81.38% of the companies are valued more expensively.
NEOG is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 34.62, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.4 | ||
| Fwd PE | 18.51 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NEOG is valued a bit cheaper than the industry average as 74.47% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 20.75 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.51%
EPS Next 3Y6.43%
5. Dividend
5.1 Amount
No dividends for NEOG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
6.42
+0.03 (+0.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners112.45%
Inst Owner Change2.82%
Ins Owners0.42%
Ins Owner Change90.55%
Market Cap1.40B
Revenue(TTM)886.89M
Net Income(TTM)-1.04B
Analysts76.36
Price Target7.78 (21.18%)
Short Float %10.75%
Short Ratio4.16
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)30.72%
Min EPS beat(2)-34.64%
Max EPS beat(2)96.08%
EPS beat(4)2
Avg EPS beat(4)15.53%
Min EPS beat(4)-34.64%
Max EPS beat(4)96.08%
EPS beat(8)2
Avg EPS beat(8)-1.35%
EPS beat(12)4
Avg EPS beat(12)52.58%
EPS beat(16)5
Avg EPS beat(16)29.73%
Revenue beat(2)1
Avg Revenue beat(2)0.03%
Min Revenue beat(2)-0.4%
Max Revenue beat(2)0.46%
Revenue beat(4)1
Avg Revenue beat(4)-0.95%
Min Revenue beat(4)-3.66%
Max Revenue beat(4)0.46%
Revenue beat(8)2
Avg Revenue beat(8)-0.99%
Revenue beat(12)3
Avg Revenue beat(12)-0.84%
Revenue beat(16)3
Avg Revenue beat(16)-1.21%
PT rev (1m)17.31%
PT rev (3m)17.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.33%
EPS NY rev (1m)-2.04%
EPS NY rev (3m)-33.33%
Revenue NQ rev (1m)0.6%
Revenue NQ rev (3m)-0.63%
Revenue NY rev (1m)0.51%
Revenue NY rev (3m)-0.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.4 | ||
| Fwd PE | 18.51 | ||
| P/S | 1.57 | ||
| P/FCF | N/A | ||
| P/OCF | 16.03 | ||
| P/B | 0.66 | ||
| P/tB | N/A | ||
| EV/EBITDA | 20.75 |
EPS(TTM)0.3
EY4.67%
EPS(NY)0.35
Fwd EY5.4%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.4
OCFY6.24%
SpS4.08
BVpS9.75
TBVpS-1.55
PEG (NY)N/A
PEG (5Y)N/A
Graham Number8.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.88% | ||
| ROE | -49.23% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.39% | ||
| FCFM | N/A |
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
F-Score3
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.37 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 8.03 | ||
| Cap/Depr | 75.94% | ||
| Cap/Sales | 10.17% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 88.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.58 | ||
| Quick Ratio | 2.26 | ||
| Altman-Z | 0.83 |
F-Score3
WACC7.71%
ROIC/WACCN/A
Cap/Depr(3y)85.8%
Cap/Depr(5y)97.5%
Cap/Sales(3y)10.58%
Cap/Sales(5y)8.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-42.86%
EPS Next Y-25.82%
EPS Next 2Y2.51%
EPS Next 3Y6.43%
EPS Next 5Y7.29%
Revenue 1Y (TTM)-2.77%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-3.58%
Revenue Next Year-7.61%
Revenue Next 2Y-3.02%
Revenue Next 3Y-1.03%
Revenue Next 5Y0.76%
EBIT growth 1Y-147.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year136.85%
EBIT Next 3Y34.71%
EBIT Next 5Y20.44%
FCF growth 1Y39.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.3%
OCF growth 3Y-5.05%
OCF growth 5Y-7.47%
NEOGEN CORP / NEOG FAQ
What is the fundamental rating for NEOG stock?
ChartMill assigns a fundamental rating of 3 / 10 to NEOG.
Can you provide the valuation status for NEOGEN CORP?
ChartMill assigns a valuation rating of 3 / 10 to NEOGEN CORP (NEOG). This can be considered as Overvalued.
How profitable is NEOGEN CORP (NEOG) stock?
NEOGEN CORP (NEOG) has a profitability rating of 3 / 10.
What is the earnings growth outlook for NEOGEN CORP?
The Earnings per Share (EPS) of NEOGEN CORP (NEOG) is expected to decline by -25.82% in the next year.